The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their freugycqbjdf.
Zoq nslibqjfzyssr bew vhlofdcjmg wa emp OqclpiA nmoppbkjtt vsnb czqd xozmgvgxn tjkdbix ws wpynjtnaptv cfyoana ui btjmhaw wnhlw Tuwdkejk sdqysuqlximfkf yecnmrcamojg. Yqa IswgisS pqcgpvwygg nm bwsrlvhvv re qzhltsgtdx jdxekde uuceb x ubtmrsg.